NCT04927169 (ILIAD-7-BRA) is a Phase 2 clinical trial of Interleukin-7 in COVID-19, sponsored by Revimmune.

Who is sponsoring NCT04927169?

NCT04927169 is sponsored by Revimmune.

What drugs are being tested in NCT04927169?

Interventions in NCT04927169: Interleukin-7, PLACEBO.

What condition does NCT04927169 study?

NCT04927169 studies COVID-19, Lymphocytopenia.

Is NCT04927169 still recruiting?

NCT04927169 is currently terminated. Last updated 12 April 2024.

Last reviewed 2024-04-12 · How we verify

NCT04927169: ILIAD-7-BRA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)

Terminated Phase 2 Last updated 12 April 2024

What this trial tests

Phase 2 trial testing Interleukin-7 in COVID-19 in 4 participants. Terminated before completion.

Timeline

1 March 2021

Primary endpoint
31 December 2021

30 March 2022

Quick facts

Lead sponsor	Revimmune
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	4
Start date	1 March 2021
Primary completion	31 December 2021
Estimated completion	30 March 2022
Sites	6 locations across Brazil

Drugs / interventions tested

Interleukin-7 — full drug profile →
PLACEBO

Conditions studied

COVID-19 — all drugs for COVID-19 →
Lymphocytopenia — all drugs for Lymphocytopenia →

Sponsor

Revimmune — full company profile →

Who can join

Adults 25 to 80, any sex, with COVID-19 or Lymphocytopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparison of the effects of CYT107 vs Placebo administered by intra-muscular route (IM) at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

IL-7 in SARS-CoV-2 Infection and as a Potential Vaccine Adjuvant.
Bekele Y, Sui Y, Berzofsky JA. · · 2021 · cited 32× · PMID 34603318 · DOI 10.3389/fimmu.2021.737406
A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19.
Shankar-Hari M, Francois B, Remy KE, Gutierrez C, et al · · 2025 · cited 12× · PMID 39903535 · DOI 10.1172/jci.insight.189150
Targeting immunosenescence in lung diseases: mechanistic insights and clinical interventions.
Zhang Y, Yu X, Li P, Ouyang Y, et al · · 2026 · PMID 41952158 · DOI 10.1186/s12916-026-04833-9

Verify or expand the search:

Other trials of Interleukin-7

Trials testing the same drug.

NCT04407689 — InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort · Phase 2 · terminated
NCT04379076 — InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort · Phase 2 · terminated
NCT02797431 — Immune Reconstitution of Immunosuppressed Sepsis Patients · Phase 2 · terminated

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Revimmune trials

Trials by the same sponsor.

NCT04426201 — InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) · Phase 2 · terminated
NCT04154826 — Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease · Phase 2 · terminated
NCT04442178 — InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ) · Phase 2 · terminated
NCT04407689 — InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort · Phase 2 · terminated
NCT04379076 — InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04927169 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Revimmune
Last refreshed: 12 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04927169.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing